Close Menu

NEW YORK – Three decentralized tests for SARS-CoV-2, the virus that causes COVID-19, have been granted Emergency Use Authorization from the US Food and Drug Administration in the past 10 days. But whether deploying testing closer to patients will fundamentally change how the ongoing outbreak ultimately plays out may hinge on how many tests can be quickly deployed and how clinically accurate they prove to be.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.

Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.

New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.

In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.

Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.